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Abstract: 
Introduction: Residual platelet reactivity (RPR) following coronary artery bypass grafting 
(CABG) might be related to thrombotic complications and major ischemic cardiac events. 
The aim of this study was to evaluate the changes in platelet reactivity, monitored pre- and 
postoperatively using multiple electrode aggregometry (MEA) and to propose alternative 
therapeutic approach in subgroup of patients with postoperative RPR.  
Methods: 99 patients undergoing elective CABG were enrolled in the study, of those, 41/99 
(41.4%) patients were found diabetic. Preoperatively, all patients received 100mg 
acetylsalicylic acid (ASA), and 47/99 (47.4%) of patients received additionally 75 mg 
clopidogrel (CLO). The blood samples were drawn day before surgery, first and fourth 
postoperative day. Platelet count and fibrinogen level were documented, as well as type and 
daily dose of antiplatelet therapy (APT), received pre- and postoperatively. MEA using ASPI 
and ADP test was performed day before and 4 days after surgery.  
Results: Preoperatively, we detected 31/99 (31.3%) of patients with RPR (ASPI > 30 AUC). 
Platelet count correlated with both ASPI (p=0.03) and ADP (0.002) test. Fibrinogen 
correlated with ADP test values (p<0.001) and was found to have a higher level in diabetic 
subgroup (p=0.01). Comparing to preoperative results, we detected higher values of ASPI test 
postoperatively (p=0.04) with 46/99 (46.5%) of patients with RPR despite higher dose of 300 
mg ASA administered. Postoperatively, diabetic patients had a higher ASPI test values 
(p=0.01), and higher proportion of patients with RPR comparing to non-diabetic subgroup 
(58.5% vs. 38%, p=0.04). Subgroup of patients with detected ASPI >30 AUC at fourth 
postoperative day, received consequently as a part of our clinical routine, additionally 75 mg 
CLO per day, in terms of platelet inhibition optimization. 
Conclusion: MEA can recognize patients with RPR during the both the pre- and post- CABG 
period. Postoperatively administered 300 mg ASA, did not sufficiently inhibit platelet 
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aggregation in 46.5% post CABG patients. In this group of patients switch on dual antiplatelet 
therapy should be considered.  
Key words (MeSH Terms): multiple electrode aggregometry, aspirin, coronary artery bypass, 
platelet aggregation, aspirin resistance
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Introduction 
The outcome of coronary artery bypass graft surgery (CABG) depends mainly on the patency 
of the graft vessels. Graft patency is mainly influenced by the type of the graft used, but also 
by diameter and degree of atherosclerotic changes of the distal vessel into which the graft is 
placed. Aortocoronary vein graft disease is comprised of three distinct but interrelated 
pathological processes: thrombosis, intimal hyperplasia and atherosclerosis [1]. Early 
thrombosis is a major cause of vein graft attrition during the first month after CABG. Bypass 
patency can be improved with antiplatelet therapy (APT) which is the mainstay of treatment 
for patients after CABG. Acetylsalicylic acid (ASA) is the best studied, most used and least 
toxic of the platelet inhibitors [2, 3]. A beneficial effect of ASA on vein graft patency has 
been shown during the first year after CABG [4-6]. However, some patients experience 
adverse cardiac events despite treatment with APT. Some of those events could be caused by 
residual platelet reactivity (RPR) after APT administration which inevitably suggests need for 
antiplatelet drug dose increase, or administration of another antiplatelet agent as a 
supplement. RPR after ASA or clopidogrel (CLO) administration, as assessed by platelet 
function tests, varies widely among patients, and has been reported to range from 1 to 45% for 
the 2 drugs [7]. RPR following CABG might be related to thrombotic complications and 
major ischemic cardiac events. This phenomenon has already been described in literature [8, 
9]. RPR can postoperatively be presented as a non-reactive state of platelets to APT. 
Recently, a new point-of-care assay named multiple electrode aggregometry (MEA) using a 
device called Multiplate analyzer (Dynabyte, Munich, Germany) has become available at our 
department for rapid and standardized assessment of platelet function parameters. The aim of 
this study was to evaluate the RPR using MEA, both pre- and postoperatively in patients 
following CABG, and to propose the alternative therapeutic approach to patients with 
observed postoperative RPR to ASPI test. APT in diabetes, however, is still a matter of 
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intense debate due to a high prevalence of RPR, described elsewhere [10]. Additional aim of 
our study was to clarify whether diabetic patients following CABG showed a higher rate of 
RPR after ASA administration. 
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Materials and methods 
Patient selection 
The study was conducted in a prospective observational mode. After institutional review 
board approval and written informed consent, 99 adult men and women scheduled for elective 
CABG requiring cardiopulmonary bypass (CPB) between August 2009 and March 2010 were 
prospectively studied. Criteria for excluding patients from the group of subjects were: missing 
consent, patients with cardiac surgical procedures other than isolated CABG, on APT other 
than ASA or CLO, patients with inaccurate APT administration documentation or missing 
data, an urgent surgery, off-pump CABG, redo CABG. In our study cohort APT was 
administered by the referral cardiologist. All patients were admitted to our department with 
daily dose of 100 mg ASA which was continued up to day of surgery. 47/99 (47.4%) of 
patients received daily dose of 75 mg CLO in addition to ASA, and CLO was excluded at our 
department prior to surgery with individually different time interval from CLO cessation to 
surgery, from 2 to 8 days, respectively. Time from CLO cessation to surgery varied 
individually, based on the date of admission to our department and the date of procedure. 
Patients received APT continuously at least for 10 days prior to admission to our department. 
Perioperative management:  
All patients had the same anesthetic and perfusion teams, and were admitted at least 1 day 
before surgery. Surgery was performed in a single unit with standard surgical techniques. 
Anesthesiologists and surgeons were blinded to the preoperative results of the MEA 
measurements.  
The patients received diazepam and morphine 30 min prior to the induction of anesthesia. 
Endotracheal tube, urinary catheter, as well as radial artery and pulmonary artery catheters 
were inserted. The anesthetic regime included induction and maintenance of anesthesia with 
midazolam, fentanyl and pancuronium bromide. This was coupled with sevoflurane 
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inhalation. The initial ventilator settings included a tidal volume of 8 ml kg_1, and a 
respiratory rate of 12 breaths per minute. Typically, the FiO2 was set at 50%. 
Cardiopulmonary circuit consisted of the Medtronic Affinity Trillium membrane oxygenator, 
venous reservoir and PVC tubing (Medtronic, Minneapolis, MN, USA) and a Stoeckert III 
roller pump (Stoeckert, Munich, Germany). It was established via central cannulation, 
targeting flow at 2.2 l min-1 m-2 and mean blood pressure of 60 mmHg. Heart was arrested 
with cold blood cardioplegia. Systemic heparinisation aiming at an activated clotting time 
>480 s was used, followed by full reversal with protamine after decannulation. A dose 
of 1 g tranexamic acid was given at the induction of anesthesia and after protamine 
administration. Inotropic support was initiated in order to maintain a cardiac index greater 
than 2.2 l min-1 m-2. Arterial and venous grafts were used for bypass diseased coronary 
vessels. The lungs were open to atmosphere during CPB. Weaning from CPB was initiated 
once the patient’s rhythm had stabilized and normothermia had been achieved. Packed red 
blood cells were added during CPB if the hematocrit level was <20%. Volume replacement in 
the intensive care unit was administered as deemed necessary by the attending physician 
using hydroxyethyl starch 6% 130/0.4 and lactated Ringer's solution, Packed red blood cells 
were transfused if deemed necessary by the consultant anesthesiologist. 
Blood Sampling: 
Blood samples for MEA measurements were obtained day before surgery and fourth 
postoperative day using venipuncture, and blood was collected in 4 ml heparin (Lithium 
Heparin 68 I.U.) coated BD Vacutainer
®
 plastic tubes. Routine laboratory tests were 
performed each day from day before surgery to fourth postoperative day. The same person, 
not directly involved in patient care, performed all measurements. Blood samples were at rest 
for 30 minutes after blood withdrawal and MEA was performed subsequently. 
Multiple electrode aggregometry (MEA): 
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Whole blood aggregation was determined using a new generation impedance aggregometer 
(Multiplate
®
 analyzer, Dynabyte Medical, Munich). Detailed description of method has 
already been published [11]. Put briefly, MEA is based on the principle that blood platelets 
are non-thrombogenic in their resting state, but expose receptors on their surface when they 
get activated, which allow them to attach on vascular injuries and artificial surfaces. When 
platelets stick on the Multiplate sensor wires, they enhance the electrical resistance between 
them, which is continuously recorded. Increase in impedance is expressed in arbitrary area 
under curve (AUC) units, highlighted as the parameter with the highest diagnostic power [11, 
12]. The analysis itself needs 3 min for incubation and 6 min for the measurement after 
stimulation. Platelet aggregation was determined in response to stimulation with arachidonic 
acid with a final concentration of 0.5 mM (ASPI test designed to evaluate ASA effect) and 
adenosine diphosphate (ADP) with a final concentration of 6.4µM (ADP test designed to 
evaluate thienopyridines, such as CLO, effect). RPR to ASPI aggregation test was defined by 
an AUC of >30 U (75th percentile of aggregation in ASPI test from 65 control patients with 
coronary artery disease on chronic 100 mg ASA daily treatment, scheduled for CABG) [13]. 
This definition is in concordance to literature sources published by our institutional colleagues 
with the same setting used in cohort of 110 patients with stable coronary artery disease 
receiving daily dose of 100 mg ASA [14]. Similar results, although with different 
anticoagulant used for blood sampling for MEA were also described [15, 16]. 
Statistical analysis: 
For statistical analysis we used MedCalc® For Windows software. MedCalc Software, 
Broekstraat 52, 9030 Mariakerke, Belgium. The Kolmogorov-Smirnov test was used for 
evaluating normality of distribution of all continuous variables. Independent t-test was used 
for two study groups’ comparison. Chi square test was used for data comparison between 
groups. Value of p≤0.05 was considered statistically significant.  
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Results 
Patients 
All patients from the sample were discharged from hospital. Cohort group was divided in the 
two subgroups regarding preoperative APT. We observed RPR both pre- and postoperatively. 
No difference occurred among the study group concerning age, sex, and weight. Perioperative 
laboratory values (hemoglobin, hematocrit, platelet count and fibrinogen level) did not differ 
among the patients. Descriptive statistics of two groups is presented in Table 1a and 1b.  
Platelet count, fibrinogen level, platelet aggregation assessment and residual platelet reactivity 
prevalence  
Considering all CABG patients, we observed 31/99 (31.3%) patients with RPR (ASPI > 30 
AUC) preoperatively with no significant difference among the groups regarding APT 
administered preoperatively (Table 1b). Following the routine clinical protocol, all patients 
received 300mg ASA postoperatively, starting at first postoperative day. At fourth 
postoperative day we registered 46/99 (46.5%) CABG patients with RPR despite higher dose 
of APT, suggesting platelet hyperactivity. Postoperatively registered increase of 15.2% in 
proportion of patients with RPR was found to be significant, p=0.04. In the group of patients 
with preoperative registered RPR (n=31), we found in proportion of 18/31 patients (58.1%) 
with RPR after surgery, while in group with preoperatively adequate platelet inhibition (n=68) 
we registered proportion of 28/68 patients (41.1%) with RPR postoperatively. Higher amount 
of patients with preoperative RPR were found to have RPR in postoperative period, but the 
difference didn't reach statistical significance. 
Postoperatively, we detected higher values of both ASPI test, (p= 0.04, shown in Figure 2) 
and ADP test (p= 0.002, shown in Figure 3) in comparison to preoperative results.  
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In addition to above mentioned results which suggests postoperative RPR proportion increase, 
we have found a significant (p<0.001) perioperative increase in fibrinogen level (Figure 1). 
Platelet count and fibrinogen were correlated with ASPI and ADP test both pre- and 
postoperatively. Preoperatively, we detected significant correlation between platelet count and 
both ASPI (p=0.03) and ADP test (p=0.002). Fibrinogen correlated significantly with ADP 
test values (p<0.001). At fourth postoperative day, only platelet count and ADP test correlated 
significantly (p=0.01). 
Residual platelet reactivity and diabetes mellitus 
We analyzed the difference in the degree of platelet inhibition among patients with respect to 
the presence of diabetes as a comorbidity, both pre-and postoperatively (Table 2). We found 
that 41/99 (41.4%) patients were diabetic. In this subgroup of patients, preoperative 
evaluation of platelet inhibition, revealed 16/41 (39%) of patients with RPR versus 15/58 
(25.9%) in non-diabetic subgroup, and the difference was found to be non-significant. We 
registered higher fibrinogen level in diabetic population preoperatively with respect to non-
diabetic patients (4.15 g/L, σ 1.06 vs. 3.66 g/L, σ 0.87, p=0.01). Postoperative evaluation of 
platelet inhibition revealed 24/41 (58.5%) of patients with RPR in diabetic subgroup versus 
22/58 (38%) in non-diabetic group, and the difference in proportion of patients with RPR 
among 2 groups was significant (p=0.04). Diabetic patients subgroup had a significant higher 
postoperative ASPI test values (40.71, σ 27.07), in comparison to non-diabetics (30.28, σ 
14.9), p= 0.01. Comparing results of preoperative and postoperative measurements, we 
registered 19.5% increase in the proportion of patients with RPR (from 16/41, 39% 
preoperatively to 24/41, 58. 5% postoperatively) in diabetic patients compared with 12.1% 
increase (from 15/58, 25.9% preoperatively to 22/58, 38% postoperatively) in the proportion 
in non-diabetics subgroup. The difference in patients with RPR proportion increase was not 
significant.  
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Residual platelet reactivity and gender 
We assessed RPR prevalence with respect to gender both pre- and postoperatively. In female 
group, preoperative assessment revealed 11/25 (44%) patients with RPR. In male group, 
20/74 (27%) patients showed RPR at same time. Postoperatively, RPR occurred in 12/25 
(48%) within female, and in 34/74 (45.9%) within male population. Although the differences 
in RPR prevalence with respect to gender were not significant both pre- and postoperatively it 
is worth mentioning that male population had postoperative RPR prevalence increase of 
18.9% versus 4% in female population. 
Of note, we noticed a non-significant difference in prevalence of diabetes mellitus among 
genders.  
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Discussion 
Our study presumably identified a group of patients with RPR to ASPI aggregation test, 
sensitive to ASA effect, both pre- and postoperatively. Platelet aggregation, assessed with 
MEA ASPI test, was not sufficiently inhibited in 46.5% post CABG patients despite 300 mg 
ASA administered postoperatively. Proportion of patients with RPR was higher 
postoperatively, despite higher daily dose of 300 mg ASA (p=0.04). 
Coronary artery disease is a leading cause of death in developing and developed countries [2, 
17]. No uniform guidelines exist for the postoperative prevention of thrombotic complications 
after CABG [18]. It is widely accepted that platelets play a pivotal role in the development of 
thrombosis [19, 20]. Early graft failure is hypothesized to be related to thrombus 
development, of which RPR may be an important component [21].  
Several laboratory assays are commonly used to assess response to APT. The fact that 
aggregation in MEA takes place on surfaces is a major difference compared to other methods 
such as Born aggregometry and single platelet counting. MEA uses anticoagulated whole 
blood for analysis. Whole blood is the physiological environment where platelet function 
takes place in vivo, and the use of whole blood for in vitro testing eliminates the need for 
time-consuming centrifugation steps required for Born aggregation measurements. The ideal 
anticoagulant for accurate platelet aggregometry remains controversial. Citrate is still now 
used as the anticoagulant of choice for platelet testing. At our department only citrate and 
heparin are available as blood sample anticoagulants. Heparin may be used as an 
anticoagulant for platelet aggregation studies [22, 23] although early literature refers heparin 
to affect aggregation results [24]. Therefore, different reference interval of test values should 
be considered. We obtained blood samples by performing anticoagulation with heparin. Truss 
et al [22] has compared aggregation data obtained performing MEA using either citrate or 
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heparin as an anticoagulant. MEA responses to arachidonic acid, ADP and collagen, obtained 
with heparin as anticoagulant resulted in lower values than data obtained with citrated blood. 
Taking into consideration the fact we regularly use unfractioned heparin as an anticoagulant 
for MEA we made our own definition of RPR. RPR to ASPI aggregation test was defined by 
an AUC of >30 U (75th percentile of aggregation in ASPI test from 65 control patients with 
coronary artery disease on chronic 100 mg ASA daily treatment, scheduled for CABG) [13].   
Antiplatelet therapy management: 
Based on our data supporting that patients after CABG have hyperactive platelets, the use of 
low molecular weight heparin as additional thromboprophylaxis may not be the optimal 
strategy, because low molecular weight heparin does not inhibit platelet function per se. 
Currently, there is no established therapeutic approach for managing low response to ASA 
that has been shown in large trials to have clinical benefit. Our data presumably identified a 
subgroup of patients with RPR following CABG who may be at increased risk for developing 
thromboembolic complications. In this subgroup of patients higher doses of ASA would not 
be prudent in terms of worsening endothelial – mediated arterial dilatation [25]. These 
patients could benefit from a more aggressive antithrombotic treatment regimen such as dual 
antiplatelet therapy with CLO addition to ASA therapy. CLO is very useful, especially taking 
into consideration the fact that our study cohort had a higher postoperative ADP aggregation 
test values (p=0.002) which can be specifically inhibited by CLO. However, this 
therapeutically approach needs randomized control trial with large study group to evaluate the 
benefit of such treatment. The benefit of such a treatment regimen has been investigated in 
CASCADE trial [26]. The authors investigated on the impact of dual antiplatelet therapy on 
venous graft disease in CABG patients. The primary outcome was saphenous vein graft 
intimal hyperplasia, determined by intravascular ultrasound. Secondary outcomes were graft 
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patency, major adverse cardiovascular events, and major bleeding. No significant difference 
occurred regarding both the primary and secondary outcomes between ASA-CLO and ASA-
placebo postoperative APT regimen group. The lack of objective quantification of the 
antiplatelet effect of both ASA and CLO constitutes a major drawback of the study [27]. 
Nevertheless, since RPR raises the incidence of adverse cardiovascular events and venous 
graft occlusions, it would seem critical to adjust for this variable [1]. This problem was 
further amplified by ignoring the variability to CLO response. Therefore, randomization of 
patients with MEA assessed inappropriate response to ASA on CLO or placebo addition 
could reveal different results. Further, MEA evaluation of response to CLO in group receiving 
dual antiplatelet therapy could be useful. Another alternative therapeutic approach is mono 
antiplatelet therapy with CLO. The Aspirin Non-Responsiveness and Clopidogrel End point 
Trial (ASCET) is currently evaluating whether switching to CLO will be superior to 
continuing  ASA therapy in improving clinical outcomes in ASA low responders [28]. Our 
study showed that diabetics are prone to have RPR after ASA administration, especially after 
CABG. Increased baseline platelet reactivity may be more commonly observed in specific 
clinical scenario such as diabetes mellitus, as described in literature [10]. APT in diabetes, is 
still a major issue due to a high prevalence of RPR after APT administration [10]. Higher 
prevalence of RPR described in our diabetic patients’ subgroup might be a major contributor 
to poorer outcomes among diabetic patients. It has been recently reported that platelet 
reactivity is tightly associated with glycemic control in diabetics [29]. Elevated glycosylated 
hemoglobin levels are common among diabetic patients scheduled for coronary surgery, 
particularly in patients receiving insulin, and are associated with more frequent occurrence of 
perioperative myocardial infarction [30]. These data suggest that diabetic patients with poor 
metabolic control and the high degree of platelet reactivity may benefit from aggressive APT 
strategies [31]. Using MEA to guide APT allowed us individual tailoring therapy after MEA 
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assessment at fourth postoperative day. Individual tailored therapeutic approach significantly 
improves clinical outcomes. Awidi et al found that the combination of ASA and CLO had 
greater inhibitory effects on platelet function than either agent alone [2]. However, we found 
no significant difference in the proportion of low-responders to ASA between groups with 
respect to preoperative APT regime strategy. The reasons for such a difference may be the 
fact that CABG undergoing patients are those who may be considered 'treatment failures' 
following percutaneous coronary interventions, as described by Preisman et al [32]. 
Prospective, outcome evaluating randomized trials, with platelet function assessment are 
needed to clarify the benefits of dual antiplatelet therapy. 
Using thromboelastography for assessment of platelet function Bochsen et al suggested that 
CABG patients are prone to platelet hyperactivity at fourth postoperative day [8]. Although 
revealed with different assay, study described the same phenomenon as we did. Using 
modified TEG with arachidonic acid as platelet agonist Preisman S et al showed 44% rate of 
non-responsiveness to aspirin [32]. Using the turbidimetric method for platelet aggregation 
measuring, Kempfert et al reported 28.8% patients with RPR before CABG. Postoperatively 
almost half of patients (49%) developed RPR [33]. These results are similar to the results of 
our study, although it is worth mentioning that the patients had different postoperative ASA 
dosing regimens compared with patients in our study. Standard definition to assess 
antiplatelet drug response has not been fully established and differences in assays, agonist 
concentrations and cut-off values have contributed to the existing variability [7]. Antiplatelet 
response to ASA, as assessed by platelet function tests, varies widely among the patients, and 
that could possibly explain early graft occlusion within the first month after surgery despite 
appropriate ASA treatment [4]. These results suggest that a more aggressive antithrombotic 
treatment might be warranted for patients undergoing CABG in postoperative period. 
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Limitations of study 
We have not performed an in house reference interval of normal values of platelet aggregation 
assessed by MEA with arachidonic acid and ADP as agonists by using heparin as 
anticoagulant. In addition to, in house studies of imprecision of the method have not been 
performed. Hemostatic studies are usually performed on citrated blood samples. Due to fact 
that heparin has been used as anticoagulant in our study, differently by the other authors, we 
obtained cut off value for RPR, by using the same setting in the 65 consecutive patients 
requiring CABG. 
The study was conducted as prospective observational, and we did not analyze the outcome 
with respect to MEA results and subsequent APT adjustment. The purpose of study was to 
evaluate RPR prevalence both pre- and postoperatively, with APT adjustment proposal in 
RPR appearance. Our study contained no randomization, and the scope of this study was not 
to identify the event rate of thromboembolic complication with regards to MEA results.  
The impact of dual antiplatelet therapy on cardiovascular ischemic events reduction was not 
evaluated. We did not repeat MEA measurements after APT adjustment so did not distinguish 
whether the RPR was permanent or temporary. Although we assessed ADP test both pre- and 
postoperatively we did not assessed preoperatively RPR to ADP test with respect to CLO 
administration. The reason is in the fact that measurements were performed the day before 
surgery, and CLO was excluded from therapy in different  time intervals from measurements, 
so technically it would be impossible to mark someone to be CLO resistant, i.e. 5 days after 
CLO withdrawal. 
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However, the use of MEA ADP test, sensitive to CLO effect, was useful because it showed a 
significant increase (p=0.002) in values in the postoperative period, which inevitably suggests 
the use of CLO in patients with detected postoperatively RPR to ASPI test. 
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Tables 
Table 1. 
a) Descriptive statistics of patient groups according to preoperative antiplatelet therapy 
administered  
b) Basic demographic and operative data  
 *monotherapy group (acetylsalicylic acid), 
†
dual antiplatelet therapy group (acetylsalicylic 
acid and clopidogrel), 
‡
 fourth postoperative day, 
§
 residual platelet reactivity to ASPI 
aggregation test
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a) 
 
Groups N Mean σ  
P (Mann-
Whitney U 
test) 
Platelet count preoperative 
(x109/L) 
ASA* 52 209.8 58.2 
0.166 
DAT† 47 224.7 61.8 
Fibrinogen (g/L) 
preoperative 
ASA 51 3.8 0.9 
0.508 
DAT 47 3.9 1.0 
Cardiopulmonary bypass 
time (min) 
ASA 52 95.5 27.4 
0.009 
DAT 47 82.5 32.6 
ASPI test preoperative 
(AUC) 
ASA 52 29.4 26.2 
0.674 
DAT 47 28.9 20.1 
ADP test preoperative 
(AUC) 
ASA 52 60.0 24.7 
0.188 
DAT 47 54.4 24.4 
ASPI test POD 4‡ (AUC) 
ASA 52 33.9 19.2 
0.972 
DAT 46 35.5 23.8 
ADP test POD 4‡ (AUC) 
ASA 52 69.9 30.8 
0.524 
DAT 46 68.9 39.8 
Platelet count POD 4‡   
(x109/L) 
ASA 52 188.9. 75.5. 
0.408. 
DAT 47 198.5 73.1 
Fibrinogen (g/L) POD 4‡ 
ASA 52 7.1 1.1 
0.254 
DAT 47 7.3. 1.2. 
Age (years) 
ASA 52 64.8 8.0 
0.416 
DAT 47 63.4 7.8 
Body mass index (kg/m2) 
ASA 52 28.3 4.1 
0.494 
DAT 47 28.9 3.9 
Euro SCORE (%) 
ASA 52 3.2 3.2 
0.628 
DAT 47 2.8 2.5 
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b) 
 
Groups P (Chi-
square test 
with Yates 
correction) 
ASA* DAT† 
Count % Count % 
Gender 
Male 40 76.9% 34 72.3% 
0.770 
Female 12 23.1% 13 27.7% 
Diabetes 
mellitus 
No 29 55.8% 29 61.7% 
0.693 
Yes 23 44.2% 18 38.3% 
Preoperative 
RPR§ 
No 37 71.2% 31 66.0% 
0.734 
Yes 15 28.8% 16 34.0% 
Postoperative 
RPR§ 
No 26 50.0% 27 57.4% 
0.589 
Yes 26 50.0% 20 42.6% 
Smoking 
No 32 61.5% 27 57.4% 
0.834 
Yes 20 38.5% 20 42.6% 
Hypertension 
No 6 11.5% 4 8.5% 
0.869 
Yes 46 88.5% 43 91.5% 
Hyperlipidemia 
No 10 19.2% 2 4.3% 
0.028 
Yes 41 78.8% 45 95.7% 
No Grafts 
1 0 .0% 3 6.4% 
0.052 
2 21 40.4% 23 48.9% 
3 31 59.6% 19 40.4% 
4 0 .0% 2 4.3% 
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Table 2.  
Differences in proportion of patients with residual platelet reactivity in ASPI test both 
preoperatively and postoperatively with respect to diabetes mellitus as comorbidity. 
Preoperative phase p=0.16, Postoperative phase p= 0.04. *residual platelet reactivity to ASPI 
aggregation test 
 
Preoperative RPR* Postoperative RPR* 
Without 
RPR 
With RPR 
Without 
RPR 
With RPR 
Diabetes 
mellitus 
Without 
Diabetes 
Count 43 15 36 22 
% within 
Diabetes 
mellitus 
74.1% 25.9% 62.0% 38.0% 
With 
Diabetes 
Count 25 16 17 24 
% within 
Diabetes 
mellitus 
61.0% 39.0% 41.5% 58.5% 
Total 
Count 68 31 53 46 
% within 
Diabetes 
mellitus 
68.7% 31.3% 53.5% 46.5% 
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